Brokerages Set Collegium Pharmaceutical, Inc. (NASDAQ:COLL) PT at $43.80

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) has earned a consensus rating of “Moderate Buy” from the five research firms that are covering the stock, MarketBeat reports. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. The average 1 year target price among analysts that have issued ratings on the stock in the last year is $43.80.

Several equities analysts recently commented on COLL shares. Needham & Company LLC upgraded shares of Collegium Pharmaceutical from a “hold” rating to a “buy” rating and set a $46.00 target price for the company in a research note on Friday, January 10th. StockNews.com cut shares of Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, October 23rd. HC Wainwright restated a “buy” rating and set a $50.00 price target on shares of Collegium Pharmaceutical in a research note on Friday, January 10th. Finally, Piper Sandler reiterated a “neutral” rating and issued a $37.00 price objective on shares of Collegium Pharmaceutical in a research report on Friday, October 11th.

Collegium Pharmaceutical Stock Down 0.3 %

Shares of COLL stock opened at $33.35 on Monday. Collegium Pharmaceutical has a 12 month low of $28.39 and a 12 month high of $42.29. The company has a quick ratio of 0.88, a current ratio of 0.97 and a debt-to-equity ratio of 3.43. The firm has a market cap of $1.08 billion, a PE ratio of 14.38 and a beta of 0.82. The stock has a 50 day moving average of $30.54 and a 200-day moving average of $34.12.

Insiders Place Their Bets

In other Collegium Pharmaceutical news, EVP Shirley R. Kuhlmann sold 27,500 shares of the company’s stock in a transaction on Friday, January 10th. The stock was sold at an average price of $33.04, for a total value of $908,600.00. Following the sale, the executive vice president now directly owns 119,184 shares in the company, valued at $3,937,839.36. This represents a 18.75 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Corporate insiders own 3.98% of the company’s stock.

Institutional Investors Weigh In On Collegium Pharmaceutical

Several institutional investors and hedge funds have recently made changes to their positions in COLL. JPMorgan Chase & Co. lifted its holdings in Collegium Pharmaceutical by 173.6% during the 3rd quarter. JPMorgan Chase & Co. now owns 277,204 shares of the specialty pharmaceutical company’s stock valued at $10,711,000 after purchasing an additional 175,892 shares during the last quarter. Penserra Capital Management LLC acquired a new position in shares of Collegium Pharmaceutical in the 3rd quarter worth approximately $757,000. Barclays PLC grew its position in Collegium Pharmaceutical by 152.2% during the 3rd quarter. Barclays PLC now owns 75,052 shares of the specialty pharmaceutical company’s stock worth $2,899,000 after acquiring an additional 45,291 shares during the last quarter. Squarepoint Ops LLC increased its holdings in Collegium Pharmaceutical by 194.5% during the 2nd quarter. Squarepoint Ops LLC now owns 110,338 shares of the specialty pharmaceutical company’s stock valued at $3,553,000 after purchasing an additional 72,874 shares in the last quarter. Finally, Renaissance Technologies LLC raised its position in Collegium Pharmaceutical by 8.0% in the 2nd quarter. Renaissance Technologies LLC now owns 1,531,498 shares of the specialty pharmaceutical company’s stock valued at $49,314,000 after purchasing an additional 113,300 shares during the last quarter.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.